Posted by Michael Wonder on 01 Jun 2026
AbbVie announces European Commission authorisation of expanded label for Venclyxto (venetoclax) to include additional combinations in previously untreated chronic lymphocytic leukaemia
29 May 2026 - AbbVie today announced that the European Commission (EC) has authorised an expanded label for Vencylxto (venetoclax) to include use in combination with acalabrutinib (with or without obinutuzumab) and use in combination with ibrutinib for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia.
The expanded label follows the EC's inclusion of these combinations in the acalabrutinib and ibrutinib labels.
